# Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

> **NCT00336024** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 91 (actual)

## Conditions studied

- Anaplastic Medulloblastoma
- Medulloblastoma
- Supratentorial Embryonal Tumor, Not Otherwise Specified
- Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin Calcium
- **DRUG:** Methotrexate
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Thiotepa
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT00336024
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-22
- **Primary completion:** 2016-12-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2026-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336024, "Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00336024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*